MA-ECHOSENS
7.6.2022 18:13:07 CEST | Business Wire | Press release
Echosens , a high-technology company offering the FibroScan® portfolio of solutions, is pleased to announce that the “American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings ” states that transient elastography (TE) is preferred to quantify liver fat (CAP) and fibrosis vibration-controlled transient elastography (VCTE) for risk stratification. These guidelines make it very clear that to stage the risk of fibrosis in people with nonalcoholic fatty liver disease (NAFLD), clinicians should choose VCTE – exemplified by FibroScan – as the best validated to identify advanced disease and predict liver-related outcomes.
To learn more read the fact sheet:
US: https://www.echosens.com/en-us/aace-clinical-practice-guidelines-2022/
Global: https://www.echosens.com/aace-clinical-practice-guidelines-2022/
“This technology offers the ideal way to identify patients at risk early to prevent the development of cirrhosis and comorbidities based on screenings with an individual’s liver fibrosis risk (FIB-4),” says Dominique Legros, Group CEO, Echosens. “This should be followed by additional plasma biomarkers and/or liver imaging based on fibrosis risk stratification into low, indeterminate or high risk of developing future cirrhosis, with referral to a liver specialist for those in the higher-risk groups.”
As a pioneer in the field of liver-related elastography, FibroScan is recognized worldwide as the non-invasive gold standard solution for liver fibrosis and liver steatosis assessment with more than 3,500 peer reviewed publications. This non-invasive technology quickly provides at the point of care, a quantitative assessment of liver stiffness and controlled attenuation parameter (CAP), which correlate with liver fibrosis and fat, respectively.
The AACE guidelines further state that it is prudent to consider repeat testing every two years for those at low risk, given that one study showed that only a minority will progress to a higher fibrosis stage within that period of time.
Legros adds, “Screening is important because early intervention can halt or reverse disease progression. In a recent study as referenced in the guidelines, in persons with Type 2 diabetes, screening for NAFLD followed by intensive lifestyle interventions was cost-effective, providing further support for screening recommendations. VCTE is the most broadly used noninvasive method for LSM and, thus, for establishing the risk of liver fibrosis and eventually for excluding cirrhosis.”
Because NAFLD is usually asymptomatic, point-of-care examinations, monitoring and ongoing assessment of liver fat and stiffness as provided by FibroScan can more cost-effectively identify individuals who are asymptomatic and undiagnosed for liver damage. It can also provide metrics for monitoring changes in liver fat due to lifestyle modification.
Jon Gingrich, CEO, Echosens North America, adds, “We are thrilled by the results of this research and for the broad consensus that screening and early intervention for obesity, prediabetes, dyslipidemia and hypertension are warranted. VCTE as provided by FibroScan is cost-effective, safe and allows for interventions to prevent diabetic complications and cardiovascular events.”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®
, the non-invasive solution for comprehensive management of liver health. FibroScan®
is recognized worldwide and validated by over 3,500 peer reviewed publications and 160 international guidelines. Echosens has made FibroScan®
available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006099/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 14:30:00 CET | Press release
Klarna is Adyen’s first non-card, local payment method for agentic commerce Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specificat
SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release
India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
